Viloxazine expands the range of non-stimulant treatment options for ADHD and represents a successful example of drug repurposing in neuropsychiatry. Current evidence supports its efficacy and acceptable tolerability across the lifespan, particularly for patients who do not tolerate or respond adequately to stimulants. Nevertheless, evidence for its use beyond ADHD remains limited, and future studies should focus on head-to-head comparisons with other ADHD therapies, long-term safety and efficacy, predictors of response, and potential off-label psychiatric applications.
Mansour et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: